195 related articles for article (PubMed ID: 31158747)
1. C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays.
Le Bihan YV; Lanigan RM; Atrash B; McLaughlin MG; Velupillai S; Malcolm AG; England KS; Ruda GF; Mok NY; Tumber A; Tomlin K; Saville H; Shehu E; McAndrew C; Carmichael L; Bennett JM; Jeganathan F; Eve P; Donovan A; Hayes A; Wood F; Raynaud FI; Fedorov O; Brennan PE; Burke R; van Montfort RLM; Rossanese OW; Blagg J; Bavetsias V
Eur J Med Chem; 2019 Sep; 177():316-337. PubMed ID: 31158747
[TBL] [Abstract][Full Text] [Related]
2. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.
Westaway SM; Preston AG; Barker MD; Brown F; Brown JA; Campbell M; Chung CW; Drewes G; Eagle R; Garton N; Gordon L; Haslam C; Hayhow TG; Humphreys PG; Joberty G; Katso R; Kruidenier L; Leveridge M; Pemberton M; Rioja I; Seal GA; Shipley T; Singh O; Suckling CJ; Taylor J; Thomas P; Wilson DM; Lee K; Prinjha RK
J Med Chem; 2016 Feb; 59(4):1370-87. PubMed ID: 26771203
[TBL] [Abstract][Full Text] [Related]
3. 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.
Bavetsias V; Lanigan RM; Ruda GF; Atrash B; McLaughlin MG; Tumber A; Mok NY; Le Bihan YV; Dempster S; Boxall KJ; Jeganathan F; Hatch SB; Savitsky P; Velupillai S; Krojer T; England KS; Sejberg J; Thai C; Donovan A; Pal A; Scozzafava G; Bennett JM; Kawamura A; Johansson C; Szykowska A; Gileadi C; Burgess-Brown NA; von Delft F; Oppermann U; Walters Z; Shipley J; Raynaud FI; Westaway SM; Prinjha RK; Fedorov O; Burke R; Schofield CJ; Westwood IM; Bountra C; Müller S; van Montfort RL; Brennan PE; Blagg J
J Med Chem; 2016 Feb; 59(4):1388-409. PubMed ID: 26741168
[TBL] [Abstract][Full Text] [Related]
4. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.
Westaway SM; Preston AG; Barker MD; Brown F; Brown JA; Campbell M; Chung CW; Diallo H; Douault C; Drewes G; Eagle R; Gordon L; Haslam C; Hayhow TG; Humphreys PG; Joberty G; Katso R; Kruidenier L; Leveridge M; Liddle J; Mosley J; Muelbaier M; Randle R; Rioja I; Rueger A; Seal GA; Sheppard RJ; Singh O; Taylor J; Thomas P; Thomson D; Wilson DM; Lee K; Prinjha RK
J Med Chem; 2016 Feb; 59(4):1357-69. PubMed ID: 26771107
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design and discovery of potent and selective KDM5 inhibitors.
Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
[TBL] [Abstract][Full Text] [Related]
6. Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.
Korczynska M; Le DD; Younger N; Gregori-Puigjané E; Tumber A; Krojer T; Velupillai S; Gileadi C; Nowak RP; Iwasa E; Pollock SB; Ortiz Torres I; Oppermann U; Shoichet BK; Fujimori DG
J Med Chem; 2016 Feb; 59(4):1580-98. PubMed ID: 26699912
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Properties of a Benzimidazole Benzylpyrazole Lysine Demethylase Inhibitor: Mechanism-of-Action, Binding Site Analysis, and Activity in Cellular Models of Prostate Cancer.
Carter DM; Specker E; Małecki PH; Przygodda J; Dudaniec K; Weiss MS; Heinemann U; Nazaré M; Gohlke U
J Med Chem; 2021 Oct; 64(19):14266-14282. PubMed ID: 34555281
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Screening of Tetrazolylhydrazide Inhibitors versus KDM4 Histone Demethylases.
Małecki PH; Rüger N; Roatsch M; Krylova O; Link A; Jung M; Heinemann U; Weiss MS
ChemMedChem; 2019 Nov; 14(21):1828-1839. PubMed ID: 31475772
[TBL] [Abstract][Full Text] [Related]
9. Identification of a Novel Benzimidazole Pyrazolone Scaffold That Inhibits KDM4 Lysine Demethylases and Reduces Proliferation of Prostate Cancer Cells.
Carter DM; Specker E; Przygodda J; Neuenschwander M; von Kries JP; Heinemann U; Nazaré M; Gohlke U
SLAS Discov; 2017 Aug; 22(7):801-812. PubMed ID: 28346812
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
Horton JR; Engstrom A; Zoeller EL; Liu X; Shanks JR; Zhang X; Johns MA; Vertino PM; Fu H; Cheng X
J Biol Chem; 2016 Feb; 291(6):2631-46. PubMed ID: 26645689
[TBL] [Abstract][Full Text] [Related]
11. Structure of the Arabidopsis JMJ14-H3K4me3 Complex Provides Insight into the Substrate Specificity of KDM5 Subfamily Histone Demethylases.
Yang Z; Qiu Q; Chen W; Jia B; Chen X; Hu H; He K; Deng X; Li S; Tao WA; Cao X; Du J
Plant Cell; 2018 Jan; 30(1):167-177. PubMed ID: 29233856
[TBL] [Abstract][Full Text] [Related]
12. Studies on the Interaction of the Histone Demethylase KDM5B with Tricarboxylic Acid Cycle Intermediates.
Tarhonskaya H; Nowak RP; Johansson C; Szykowska A; Tumber A; Hancock RL; Lang P; Flashman E; Oppermann U; Schofield CJ; Kawamura A
J Mol Biol; 2017 Sep; 429(19):2895-2906. PubMed ID: 28827149
[TBL] [Abstract][Full Text] [Related]
13. Development of 2-aryl substituted quinazolin-4(3H)-one, pyrido[4,3-d]pyrimidin-4(3H)-one and pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as microsomal prostaglandin E(2) synthase-1 inhibitors.
Banerjee A; Pawar MY; Patil S; Yadav PS; Kadam PA; Kattige VG; Deshpande DS; Pednekar PV; Pisat MK; Gharat LA
Bioorg Med Chem Lett; 2014 Oct; 24(20):4838-44. PubMed ID: 25260492
[TBL] [Abstract][Full Text] [Related]
14. Lysine-241 Has a Role in Coupling 2OG Turnover with Substrate Oxidation During KDM4-Catalysed Histone Demethylation.
Hancock RL; Abboud MI; Smart TJ; Flashman E; Kawamura A; Schofield CJ; Hopkinson RJ
Chembiochem; 2018 May; 19(9):917-921. PubMed ID: 29443450
[TBL] [Abstract][Full Text] [Related]
15. Rational design, synthesis and biological profiling of new KDM4C inhibitors.
Letfus V; Jelić D; Bokulić A; Petrinić Grba A; Koštrun S
Bioorg Med Chem; 2020 Jan; 28(1):115128. PubMed ID: 31784197
[TBL] [Abstract][Full Text] [Related]
16. Substrate- and cofactor-independent inhibition of histone demethylase KDM4C.
Leurs U; Lohse B; Rand KD; Ming S; Riise ES; Cole PA; Kristensen JL; Clausen RP
ACS Chem Biol; 2014 Sep; 9(9):2131-8. PubMed ID: 25014588
[TBL] [Abstract][Full Text] [Related]
17. A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases.
Luo X; Liu Y; Kubicek S; Myllyharju J; Tumber A; Ng S; Che KH; Podoll J; Heightman TD; Oppermann U; Schreiber SL; Wang X
J Am Chem Soc; 2011 Jun; 133(24):9451-6. PubMed ID: 21585201
[TBL] [Abstract][Full Text] [Related]
18. Structural analysis of human KDM5B guides histone demethylase inhibitor development.
Johansson C; Velupillai S; Tumber A; Szykowska A; Hookway ES; Nowak RP; Strain-Damerell C; Gileadi C; Philpott M; Burgess-Brown N; Wu N; Kopec J; Nuzzi A; Steuber H; Egner U; Badock V; Munro S; LaThangue NB; Westaway S; Brown J; Athanasou N; Prinjha R; Brennan PE; Oppermann U
Nat Chem Biol; 2016 Jul; 12(7):539-45. PubMed ID: 27214403
[TBL] [Abstract][Full Text] [Related]
19. Advances in histone demethylase KDM4 as cancer therapeutic targets.
Lee DH; Kim GW; Jeon YH; Yoo J; Lee SW; Kwon SH
FASEB J; 2020 Mar; 34(3):3461-3484. PubMed ID: 31961018
[TBL] [Abstract][Full Text] [Related]
20. KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.
Chin YW; Han SY
Expert Opin Ther Pat; 2015 Feb; 25(2):135-44. PubMed ID: 25468267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
